Original rDNA Semaglutide Versus Synthetic Copies: Differences and Clinical Implications
Year: 2026
Type: article
Abstract: . However, shared nomenclature does not guarantee therapeutic equivalence. This analysis introduces the ABCDE framework (author-proposed conceptual checklist) to differentiate reference r-DNA semaglutide from synthetic or informally marketed copies. Evaluation rests on five pillars: (A) approved status, where regulatory authorization does not inherently imply interchangeability; (B) bioavailability, noting that identical exposure metrics may mask divergent impurity profiles and immunogenic risks; (C) consistency, highlighting that recombinant versus synthetic manufacturing can alter peptide stability and aggregation; (D) drug-device performance, with standardized pens helping to mitigate dosing errors that may occur with multidose vials; and (E) evidence, emphasizing that the robust clinical data from the SUSTAIN/STEP/SELECT programs are not transferable to copies. Consequently, we suggest that clinicians may find it useful to weigh product-specific evidence over label similarity when evaluating pharmacosimilars, using the ABCDE domains as a conceptual checklist (author-proposed mnemonic). Until stronger product-specific comparability evidence is available for alternative products, many clinicians may reasonably view reference semaglutide as the best-characterized option.
Source: Cureus
Institutions: Madras Diabetes Research Foundation, Dr. Mohan's Diabetes Specialities Centre, Bharti Hospital, Fortis Memorial Research Institute, Peerless Hospital & B.K.Roy Research Centre, Manipal Hospital, Diabetes Care & Hormone Clinic, Jothydev's Diabetes and Research Center, JSS Academy of Higher Education and Research, JSS Medical College and Hospital, Bhaktivedanta Hospital & Research Institute, Lilavati Hospital & Research Centre
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: diamond
OpenAlex ID: W7203971187